CoChat

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Summary: Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. This study evaluated patient-reported treatment satisfaction in EINSTEIN DVT - a large, open-label, randomised study that compared rivaroxaban with enoxaparin/ vitamin K antagonist (VKA) therapy in patients with acute symptomatic DVT without PE. As part of EINSTEIN DVT, a total of 1,472 patients in seven countries were asked to complete a new, validated measure of treatment satisfaction - the Anti-Clot Treatment Scale (ACTS) - at scheduled visits throughout 12 months of treatment. ACTS scores were compared between study groups in the intentionto- treat population. Patients reported greater satisfaction in the rivaroxaban group compared with the enoxaparin/VKA group, with higher mean ACTS scores across visits. Mean ACTS Burdens scores were 55.2 vs 52.6 (p<0.0001) in favour of rivaroxaban, equivalent to a moderate effect size of 0.42. The treatment effect was consistent over time, with the mean score difference ranging from 2.18 (month 2) to 3.18 (month 12). Overall mean ACTS Benefits scores were 11.7 vs 11.5 in favour of rivaroxaban (p=0.006). This was associated with a small overall effect size of 0.12. The improvement in ACTS Benefits for rivaroxaban became apparent at month 2 and subsequent visits. Rivaroxaban results in improved treatment satisfaction compared with enoxaparin/VKA among patients with DVT, particularly in reducing patient-reported anticoagulation burden.

Overview

Integrity signals

Registry

Crossref · 10.1160/th13-03-0243

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 46 · Cited by 86

Metadata

Authors
Bamber, L., Wang, M. Y., Prins, M. H., Ciniglio, C., Bauersachs, R., Lensing, A. W. A., & Cano, S. J.
Affiliations
  • Peninsula College of Medicine and Dentistry (GB)
  • Maastricht University Medical Centre (NL)
  • Bayer (Germany) (DE)
Corresponding author
Cano, Stefan J.
Venue
Thrombosis and Haemostasis
Published
2013
Volume
110
Issue
10
Pages
732-741
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2032267975
Cited by
86
References
46
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 7 · 2018: 10 · 2017: 5 · 2016: 14 · 2015: 13 · 2014: 13
FWCI
11.65
Type
journal article
Language
en
Open access
closed
Locations
  • Thrombosis and Haemostasis (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Funders
  • Bayer
  • Bayer HealthCare
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Health Professions › General Health Professions › Patient Satisfaction in Healthcare
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
rivaroxaban, deep vein thrombosis, enoxaparin, vitamin K antagonists, direct factor Xa inhibitors, oral anticoagulation
MeSH terms
Rivaroxaban, Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Female, Follow-Up Studies, Humans, Male, Middle Aged, Morpholines, Thiophenes, Patient Satisfaction, Enoxaparin, Venous Thrombosis, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. https://app.cochat.ai/papers/10.1160/th13-03-0243
The paper
Bamber, L., Wang, M. Y., Prins, M. H., Ciniglio, C., Bauersachs, R., Lensing, A. W. A., & Cano, S. J. (2013). Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis. https://doi.org/10.1160/th13-03-0243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.